Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Authors :: Susan Swindells
Andreas H. Diacon
Florian von Groote-Bidlingmaier
Kathleen Donahue
Naadira Vanker
Susan L. Rosenkranz
Richard Hafner
Elisa H. Ignatius
Laura Moran
Xin Sun
Sachiko Miyahara
Kelly E. Dooley
Eric L. Nuermberger
Source :: American Journal of Respiratory and Critical Care Medicine. 201:1579-1580
Publication Year :: 2020
Publisher :: American Thoracic Society, 2020.

Subjects :: Pulmonary and Respiratory Medicine
medicine.medical_specialty
Tuberculosis
business.industry
Isoniazid
MEDLINE
Pyrazinamide
Critical Care and Intensive Care Medicine
medicine.disease
Multiple drug resistance
First line treatment
Regimen
Internal medicine
Medicine
business
Rifampicin
medicine.drug

Full Text Access

Tools